SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers

Journal of Drug Targeting

Volumn 19, Issue 2, 2011, Pages 114-124

  Shubar, Hend M ^a   Lachenmaier, Sabrina ^a   Heimesaat, Markus M ^a   Lohman, Uwe ^a   Mauludin, Rachmat ^b   Mueller, Rainer H ^b   Fitzner, Rudolf ^a   Borner, Klaus ^a   Liesenfeld, Oliver ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Clinical Research Microbiology   (United States)

Author keywords

Atovaquone; Bloodbrain barrier; Gastrointestinal barrier; HPLC; Toxoplasmosis

Indexed keywords

ATOVAQUONE; DODECYL SULFATE SODIUM; NANOCOATING; POLOXAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN DISEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COATING; DRUG SYNTHESIS; DRUG UPTAKE; ENCEPHALITIS; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PARASITE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SUSPENSION; TOXOPLASMOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; BIOLOGICAL AVAILABILITY; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; EXCIPIENTS; MICE; NANOPARTICLES; POLOXAMER; SODIUM DODECYL SULFATE; SUSPENSIONS; TISSUE DISTRIBUTION; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TOXOPLASMOSIS, CEREBRAL;

EID: 78650531221     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003733995     Document Type: Article

References (40)

1. Amelsberg A, Schteingart CD, Stein J, Simmonds WJ, Sawada GA, Ho NF, Hofmann AF. (1997). Intestinal absorption of sodium dodecyl sulfate in the rodent: Evidence for paracellular absorption. Am J Physiol, 272, G498-G506. (Pubitemid 27147351)
2. Anderberg EK, Artursson P. (1993). Epithelial transport of drugs in cell culture. VIII: Effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J Pharm Sci, 82, 392-398. (Pubitemid 23150434)
3. Araujo FG, Huskinson J, Remington JS. (1991). Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother, 35, 293-299.
4. Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS. (1992). In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother, 36, 326-330.
5. Baggish AL, Hill DR. (2002). Antiparasitic agent atovaquone. Antimicrob Agents Chemother, 46, 1163-1173.
6. Boulenc X, Breul T, Gautier J-C, Saudemon P, Joyeux H, Roques C, Berger T, Fabreet G. (1995). Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial caco-2 monolayers. Int J Pharm, 123, 71-83.
7. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, Roque C, Rajicic N, McAuliffe V, Morlat P, Jayaweera DT, Vilde JL, Luft BJ. (2002). Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis, 34, 1243-1250. (Pubitemid 34450673)
8. Conley FK, Jenkins KA, Remington JS. (1981). Toxoplasma gondii infection of the central nervous system. Use of the peroxidaseantiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol, 12, 690-698.
9. Dunay IR, Heimesaat MM, Bushrab FN, Müller RH, Stocker H, Arasteh K, Kurowski M, Fitzner R, Borner K, Liesenfeld O. (2004). Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother, 48, 4848-4854. (Pubitemid 39577693)
10. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. (1994). An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int J Exp Pathol, 75, 111-116. (Pubitemid 24199772)
11. Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. (2001). Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials, 22, 2857-2865. (Pubitemid 32739242)
12. Hughes WT. (1995). The role of atovaquone tablets in treating Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol, 8, 247-252.
13. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C. (1993). Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med, 328, 1521-1527. (Pubitemid 23147781)
14. Jong A, Huang SH. (2005). Blood-brain barrier drug discovery for central nervous system infections. Curr Drug Targets Infect Disord, 5, 65-72. (Pubitemid 40467701)
15. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm Res, 26, 492-501.
16. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. (2009). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep, 58, 1-207; quiz CE1.
17. Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. (1996). Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS, 10, 1107-1112. (Pubitemid 26283348)
18. Keck CM. (2006). Cyclosporine Nanosuspensions: Optimised Size Characterisation & Oral Formulations. Berlin, Germany: Free University.
19. Kovacs JA. (1992). Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet, 340, 637-638.
20. Kreuter J, Gelperina S. (2008). Use of nanoparticles for cerebral cancer. Tumori, 94, 271-277. (Pubitemid 351838835)
21. Kuhn S, Gill MJ, Kain KC. (2005). Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg, 72, 407-409. (Pubitemid 41278848)
22. Mishra PR, Al Shaal L, Müller RH, Keck CM. (2009). Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm, 371, 182-189.
23. Montoya JG, Liesenfeld O. (2004). Toxoplasmosis. Lancet, 363, 1965-1976. (Pubitemid 38759657)
24. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63. (Pubitemid 14203433)
25. Mueller RH. (1991). Colloidal Carriers for Controlled Drug Delivery and Targeting. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
26. Nakamura T, Yamada M, Teshima M, Nakashima M, To H, Ichikawa N, Sasaki H. (2007). Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull, 30, 2360-2364. (Pubitemid 350223743)
27. Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 56, 827-840.
28. Reischl U, Bretagne S, Krüger D, Ernault P, Costa JM. (2003). Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. BMC Infect Dis, 3, 7. (Pubitemid 38671463)
29. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J. (1994). Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol, 37, 13-20. (Pubitemid 24204575)
30. Romand S, Pudney M, Derouin F. (1993). In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother, 37, 2371-2378. (Pubitemid 23324459)
31. Roux FS, Mokni R, Hughes CC, Clouet PM, Lefauconnier JM, Bourre JM. (1989). Lipid synthesis by rat brain microvessel endothelial cells in tissue culture. J Neuropathol Exp Neurol, 48, 437-447. (Pubitemid 19184789)
32. Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O. (2001). Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother, 45, 1771-1779. (Pubitemid 32466347)
33. Shakweh M, Besnard M, Nicolas V, Fattal E. (2005). Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur J Pharm Biopharm, 61, 1-13. (Pubitemid 41096683)
34. Shubar HM, Dunay IR, Lachenmaier S, Dathe M, Bushrab FN, Mauludin R, Muller RH, Fitzner R, Borner K, Liesenfeld O. (2009). The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. J Drug Target, 1-11.
35. Soukupová J, Kvítek L, Panácek A, Nevecná T, Zboril R. (2008). Comprehensive study on surfactant role on silver nanoparticles (NPs) prepared via modified Tollens process. Mater Chem Phys, 111, 77-81. (Pubitemid 351726375)
36. Sun L, Zhang C, Chen L, Liu J, Jin H, Xu H, Ding L. (2009). Preparation of alumina-coated magnetite nanoparticle for extraction of trimethoprim from environmental water samples based on mixed hemimicelles solid-phase extraction. Anal Chim Acta, 638, 162-168.
37. Teeranachaideekul V, Junyaprasert VB, Souto EB, Müller RH. (2008). Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm, 354, 6.
38. Torres RA, Weinberg W, Stansell J, Leoung G, Kovacs J, Rogers M, Scott J. (1997). Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/ Toxoplasmic Encephalitis Study Group. Clin Infect Dis, 24, 422-429. (Pubitemid 27096797)
39. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, Sun H, Huang L. (2010). The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine, 6, 170-178.
40. Zhang W, Fang XL. (2008). [Significant role of poloxamer in drug transport across blood-brain barrier]. Yao Xue Xue Bao, 43, 890-897.